BRAINSTORM CELL THERAPEUTICS INC.
BCLI · OTCMCIK 1137883fmd_1GDRGPG4R8H4TWYC141RHSKC7TManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Sep 23, 2000 to Jun 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 2 | 1 | 8 | 17 | 22 | 15 | 14 | 11 | 5 | 4 |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Operating income | (5) | (5) | (14) | (23) | (32) | (25) | (25) | (21) | (12) | (10) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | (5) | (5) | (14) | (23) | (32) | (24) | (24) | (17) | (12) | (10) |
| Income tax expense | 0 | 0 | – | – | – | – | – | – | – | – |
| Net income from continuing operations | (5) | (5) | – | – | – | – | – | – | – | – |
| Net income | (5) | (5) | (14) | (23) | (32) | (24) | (24) | (17) | (12) | (10) |